Tiago Tomazini Gonçalves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tiago Tomazini Gonçalves has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Fernanda Bruschi Marinho Priviero
Cardiovascular Translational Research Center, University of South Carolina, Columbia, SC 29209, USA
4 shared publications - Raiana dos Anjos Moraes
Cardiovascular Translational Research Center, Floyd School of Medicine, University of South Carolina, Columbia, USA
3 shared publications - Amanda Stephane Cruz dos Passos
Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil
2 shared publications - Diana L. Silva-Velasco
Cardiovascular Translational Research Center, University of South Carolina, Columbia, SC, USA.
2 shared publications - Isadora Marques Paiva
Center for Research in Inflammatory Diseases (CRID), Department of Pharmacology, and
2 shared publications - José Luiz Proenca-Modena
Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Current Sexual Health Reports
- Vol. 18 (1) , 12
Mechanistic Insights on Immune Activation-Driven Erectile Dysfunction: Evidence from Animal Models
Purpose of Review: Erectile dysfunction (ED) has traditionally been attributed to impaired hemodynamics and reduced nitric oxide (NO) bioavailability. This review examines current evidence supporting immune activation and inflammation as shared mechanisms contributing to ED across diverse pathological conditions. Recent Findings: Experimental studies demonstrate that diabetes, hypertension, obesity, aging, nerve injury, and psychological stress are associated with activation of inflammatory pathways including NF-κB, Toll-like receptors, and the NLRP3 inflammasome. These pathways interact with oxidative stress and endothelial dysfunction to promote cytokine production, fibrosis, smooth muscle loss, and inflammatory cell death. Summary: Current evidence identifies inflammatory and innate immune pathways as convergent pathogenic drivers of ED across diverse etiologies. Rather than representing passive consequences of underlying disease, these mechanisms actively contribute to vascular, neural, and structural dysfunction, perpetuating processes that promote erectile impairment. Recognizing the central role of immune-mediated dysfunction in ED may facilitate the development of novel therapeutic strategies targeting disease mechanisms rather than symptoms alone.
- 26 August 2026
- Published by Springer Nature in Current Sexual Health Reports
- Vol. 18 (1) , 12
Open AccessMechanistic Insights on Immune Activation-Driven Erectile Dysfunction: Evidence from Animal Models
Purpose of Review: Erectile dysfunction (ED) has traditionally been attributed to impaired hemodynamics and reduced nitric oxide (NO) bioavailability. This review examines current evidence supporting immune activation and inflammation as shared mechanisms contributing to ED across diverse pathological conditions. Recent Findings: Experimental studies demonstrate that diabetes, hypertension, obesity, aging, nerve injury, and psychological stress are associated with activation of inflammatory pathways including NF-κB, Toll-like receptors, and the NLRP3 inflammasome. These pathways interact with oxidative stress and endothelial dysfunction to promote cytokine production, fibrosis, smooth muscle loss, and inflammatory cell death. Summary: Current evidence identifies inflammatory and innate immune pathways as convergent pathogenic drivers of ED across diverse etiologies. Rather than representing passive consequences of underlying disease, these mechanisms actively contribute to vascular, neural, and structural dysfunction, perpetuating processes that promote erectile impairment. Recognizing the central role of immune-mediated dysfunction in ED may facilitate the development of novel therapeutic strategies targeting disease mechanisms rather than symptoms alone.
- 15 February 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (6) , 816-819
miR-127-3p as a candidate biomarker for preeclampsia: what is missing for clinical use?
- 15 February 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (6) , 816-819
miR-127-3p as a candidate biomarker for preeclampsia: what is missing for clinical use?
- Open Access
Polo-like Kinase 1 Activation Regulates Angiotensin II-Induced Contraction in Pudendal and Small Mesenteric Arteries from Mice
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase expressed in smooth muscle cells (SMCs), with emerging roles in regulating contraction. We hypothesize that PLK1 contributes to smooth muscle contractility in pudendal arteries (PA), small mesenteric arteries (SMA), and the corpus cavernosum (CC). Using male C57BL/6J mice, we assessed mRNA and protein expression of PLK1 in these tissues. In addition, the arteries and CC were mounted in myographs for isometric force measurement. We then investigated whether PLK1 regulates SMC contractility induced by phenylephrine (PE), U46619, and angiotensin II (Ang II) in arteries, and by PE, serotonin (5-HT), and electrical field stimulation (EFS; 1–16 Hz) in the CC, both in the presence and absence of the PLK1 inhibitor volasertib. PLK1 expression was confirmed in the SMA, PA, and CC by RT-qPCR or Western blotting. Notably, PLK1 inhibition significantly reduced Ang II-induced contraction in the PA and SMA and attenuated EFS-induced contraction at 2 and 4 Hz in the CC. In contrast, responses to PE, U46619, and 5-HT were unaffected by PLK1 inhibition. These results suggest that PLK1 selectively mediates contraction in response to Ang II and neurogenic stimuli. PLK1 may therefore represent a novel, stimulus-specific regulator of vascular and erectile smooth muscle contractility.
Open AccessPolo-like Kinase 1 Activation Regulates Angiotensin II-Induced Contraction in Pudendal and Small Mesenteric Arteries from Mice
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase expressed in smooth muscle cells (SMCs), with emerging roles in regulating contraction. We hypothesize that PLK1 contributes to smooth muscle contractility in pudendal arteries (PA), small mesenteric arteries (SMA), and the corpus cavernosum (CC). Using male C57BL/6J mice, we assessed mRNA and protein expression of PLK1 in these tissues. In addition, the arteries and CC were mounted in myographs for isometric force measurement. We then investigated whether PLK1 regulates SMC contractility induced by phenylephrine (PE), U46619, and angiotensin II (Ang II) in arteries, and by PE, serotonin (5-HT), and electrical field stimulation (EFS; 1–16 Hz) in the CC, both in the presence and absence of the PLK1 inhibitor volasertib. PLK1 expression was confirmed in the SMA, PA, and CC by RT-qPCR or Western blotting. Notably, PLK1 inhibition significantly reduced Ang II-induced contraction in the PA and SMA and attenuated EFS-induced contraction at 2 and 4 Hz in the CC. In contrast, responses to PE, U46619, and 5-HT were unaffected by PLK1 inhibition. These results suggest that PLK1 selectively mediates contraction in response to Ang II and neurogenic stimuli. PLK1 may therefore represent a novel, stimulus-specific regulator of vascular and erectile smooth muscle contractility.
- Open Access
- 15 May 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (21)
COVID-19-related hyperglycemia is associated with infection of hepatocytes and stimulation of gluconeogenesis
Occurrence of hyperglycemia upon infection is associated with worse clinical outcome in COVID-19 patients. However, it is still unknown whether SARS-CoV-2 directly triggers hyperglycemia. Herein, we interrogated whether and how SARS-CoV-2 causes hyperglycemia by infecting hepatocytes and increasing glucose production. We performed a retrospective cohort study including patients that were admitted at a hospital with suspicion of COVID-19. Clinical and laboratory data were collected from the chart records and daily blood glucose values were analyzed to test the hypothesis on whether COVID-19 was independently associated with hyperglycemia. Blood glucose was collected from a subgroup of nondiabetic patients to assess pancreatic hormones. Postmortem liver biopsies were collected to assess the presence of SARS-CoV-2 and its transporters in hepatocytes. In human hepatocytes, we studied the mechanistic bases of SARS-CoV-2 entrance and its gluconeogenic effect. SARS-CoV-2 infection was independently associated with hyperglycemia, regardless of diabetic history and beta cell function. We detected replicating viruses in human hepatocytes from postmortem liver biopsies and in primary hepatocytes. We found that SARS-CoV-2 variants infected human hepatocytes in vitro with different susceptibility. SARS-CoV-2 infection in hepatocytes yields the release of new infectious viral particles, though not causing cell damage. We showed that infected hepatocytes increase glucose production and this is associated with induction of PEPCK activity. Furthermore, our results demonstrate that SARS-CoV-2 entry in hepatocytes occurs partially through ACE2- and GRP78-dependent mechanisms. SARS-CoV-2 infects and replicates in hepatocytes and exerts a PEPCK-dependent gluconeogenic effect in these cells that potentially is a key cause of hyperglycemia in infected patients.
- 15 May 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (21)
Open AccessCOVID-19-related hyperglycemia is associated with infection of hepatocytes and stimulation of gluconeogenesis
Occurrence of hyperglycemia upon infection is associated with worse clinical outcome in COVID-19 patients. However, it is still unknown whether SARS-CoV-2 directly triggers hyperglycemia. Herein, we interrogated whether and how SARS-CoV-2 causes hyperglycemia by infecting hepatocytes and increasing glucose production. We performed a retrospective cohort study including patients that were admitted at a hospital with suspicion of COVID-19. Clinical and laboratory data were collected from the chart records and daily blood glucose values were analyzed to test the hypothesis on whether COVID-19 was independently associated with hyperglycemia. Blood glucose was collected from a subgroup of nondiabetic patients to assess pancreatic hormones. Postmortem liver biopsies were collected to assess the presence of SARS-CoV-2 and its transporters in hepatocytes. In human hepatocytes, we studied the mechanistic bases of SARS-CoV-2 entrance and its gluconeogenic effect. SARS-CoV-2 infection was independently associated with hyperglycemia, regardless of diabetic history and beta cell function. We detected replicating viruses in human hepatocytes from postmortem liver biopsies and in primary hepatocytes. We found that SARS-CoV-2 variants infected human hepatocytes in vitro with different susceptibility. SARS-CoV-2 infection in hepatocytes yields the release of new infectious viral particles, though not causing cell damage. We showed that infected hepatocytes increase glucose production and this is associated with induction of PEPCK activity. Furthermore, our results demonstrate that SARS-CoV-2 entry in hepatocytes occurs partially through ACE2- and GRP78-dependent mechanisms. SARS-CoV-2 infects and replicates in hepatocytes and exerts a PEPCK-dependent gluconeogenic effect in these cells that potentially is a key cause of hyperglycemia in infected patients.
- Open Access
- 29 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
SARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner
Visceral adiposity is a risk factor for severe COVID-19, and a link between adipose tissue infection and disease progression has been proposed. Here we demonstrate that SARS-CoV-2 infects human adipose tissue and undergoes productive infection in fat cells. However, susceptibility to infection and the cellular response depends on the anatomical origin of the cells and the viral lineage. Visceral fat cells express more ACE2 and are more susceptible to SARS-CoV-2 infection than their subcutaneous counterparts. SARS-CoV-2 infection leads to inhibition of lipolysis in subcutaneous fat cells, while in visceral fat cells, it results in higher expression of pro-inflammatory cytokines. Viral load and cellular response are attenuated when visceral fat cells are infected with the SARS-CoV-2 gamma variant. A similar degree of cell death occurs 4-days after SARS-CoV-2 infection, regardless of the cell origin or viral lineage. Hence, SARS-CoV-2 infects human fat cells, replicating and altering cell function and viability in a depot- and viral lineage-dependent fashion.
- 29 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Open AccessSARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner
Visceral adiposity is a risk factor for severe COVID-19, and a link between adipose tissue infection and disease progression has been proposed. Here we demonstrate that SARS-CoV-2 infects human adipose tissue and undergoes productive infection in fat cells. However, susceptibility to infection and the cellular response depends on the anatomical origin of the cells and the viral lineage. Visceral fat cells express more ACE2 and are more susceptible to SARS-CoV-2 infection than their subcutaneous counterparts. SARS-CoV-2 infection leads to inhibition of lipolysis in subcutaneous fat cells, while in visceral fat cells, it results in higher expression of pro-inflammatory cytokines. Viral load and cellular response are attenuated when visceral fat cells are infected with the SARS-CoV-2 gamma variant. A similar degree of cell death occurs 4-days after SARS-CoV-2 infection, regardless of the cell origin or viral lineage. Hence, SARS-CoV-2 infects human fat cells, replicating and altering cell function and viability in a depot- and viral lineage-dependent fashion.
- 9 November 2020
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (3) , 531-549
Exploiting oxidized lipids and the lipid‐binding GPCRs against cardiometabolic diseases
Lipids govern vital cellular processes and drive physiological changes in response to different pathological or environmental cues. Lipid species can be roughly divided into structural and signalling lipids. The former is essential for membrane composition, while the latter are usually oxidized lipids. These mediators provide beneficial effects against cardiometabolic diseases (CMDs), including fatty‐liver diseases, atherosclerosis, thrombosis, obesity, and Type 2 diabetes. For instance, several oxylipins were recently found to improve glucose homeostasis, increase insulin secretion, and inhibit platelet aggregation, while specialized pro‐resolving mediators (SPMs) are able to ameliorate CMD by shaping the immune system. These lipids act mainly by stimulating GPCRs. In this review, we provide an updated and comprehensive overview of the current state of the literature on signalling lipids in the context of CMD. We also highlight the network encompassing the lipid‐modifying enzymes and the lipid‐binding GPCRs, as well as their interactions in health and disease.
- 9 November 2020
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (3) , 531-549
Exploiting oxidized lipids and the lipid‐binding GPCRs against cardiometabolic diseases
Lipids govern vital cellular processes and drive physiological changes in response to different pathological or environmental cues. Lipid species can be roughly divided into structural and signalling lipids. The former is essential for membrane composition, while the latter are usually oxidized lipids. These mediators provide beneficial effects against cardiometabolic diseases (CMDs), including fatty‐liver diseases, atherosclerosis, thrombosis, obesity, and Type 2 diabetes. For instance, several oxylipins were recently found to improve glucose homeostasis, increase insulin secretion, and inhibit platelet aggregation, while specialized pro‐resolving mediators (SPMs) are able to ameliorate CMD by shaping the immune system. These lipids act mainly by stimulating GPCRs. In this review, we provide an updated and comprehensive overview of the current state of the literature on signalling lipids in the context of CMD. We also highlight the network encompassing the lipid‐modifying enzymes and the lipid‐binding GPCRs, as well as their interactions in health and disease.
- Open Access
- 1 July 2018
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 11, 321-332
Effects of glucosyl-hesperidin and physical training on body weight, plasma lipids, oxidative status and vascular reactivity of rats fed with high-fat diet
Objective: The aim of the study was to evaluate the effects of supplementation with glucosyl hesperidin (GH), with or without physical training, on body weight, fat depot, glucose and plasma lipids, oxidative status and vascular function of rats fed with high-fat diet (HFD). Methods: After weaning, male Wistar rats were fed with an HFD plus fructose for 12 weeks and started receiving oral antioxidant supplementation and/or physical training after the fourth week of diet for eight further weeks. Body weight, epididymal and retroperitoneal fat, plasma glucose and lipids, oxidative status and mesenteric artery reactivity were evaluated. Results: Rats fed with HFD presented higher body weight gain and fat accumulation compared to control rats, while GH supplementation did not influence these parameters. Physical training reduced the body weight gain and fat accumulation and modulated the oxidative status by increasing superoxide dismutase activity and total antioxidant capacity and reducing lipid peroxidation. GH alone decreased lipid peroxidation. However, when given to exercised rats, it impaired the response elicited by physical training. HFD caused endothelial dysfunction, and neither GH nor physical exercise prevented it. Potency of sodium nitroprusside was increased in exercised animals but not in GH-supplemented rats. Conclusion: Physical exercise partially decreased the body fat accumulation, decreased plasma levels of glucose and lipids and improved general oxidative status and endothelium-independent relaxation in mesenteric arteries of rats fed with HFD. GH exhibited benefits only in the oxidative status. However, GH given in association with physical exercise did not cause further changes in addition to those promoted by physical exercise. On the contrary, in exercised animals, GH prevented those changes elicited by physical training in plasma glucose and lipids, oxidative status and endothelium-independent relaxation.
- 1 July 2018
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 11, 321-332
Open AccessEffects of glucosyl-hesperidin and physical training on body weight, plasma lipids, oxidative status and vascular reactivity of rats fed with high-fat diet
Objective: The aim of the study was to evaluate the effects of supplementation with glucosyl hesperidin (GH), with or without physical training, on body weight, fat depot, glucose and plasma lipids, oxidative status and vascular function of rats fed with high-fat diet (HFD). Methods: After weaning, male Wistar rats were fed with an HFD plus fructose for 12 weeks and started receiving oral antioxidant supplementation and/or physical training after the fourth week of diet for eight further weeks. Body weight, epididymal and retroperitoneal fat, plasma glucose and lipids, oxidative status and mesenteric artery reactivity were evaluated. Results: Rats fed with HFD presented higher body weight gain and fat accumulation compared to control rats, while GH supplementation did not influence these parameters. Physical training reduced the body weight gain and fat accumulation and modulated the oxidative status by increasing superoxide dismutase activity and total antioxidant capacity and reducing lipid peroxidation. GH alone decreased lipid peroxidation. However, when given to exercised rats, it impaired the response elicited by physical training. HFD caused endothelial dysfunction, and neither GH nor physical exercise prevented it. Potency of sodium nitroprusside was increased in exercised animals but not in GH-supplemented rats. Conclusion: Physical exercise partially decreased the body fat accumulation, decreased plasma levels of glucose and lipids and improved general oxidative status and endothelium-independent relaxation in mesenteric arteries of rats fed with HFD. GH exhibited benefits only in the oxidative status. However, GH given in association with physical exercise did not cause further changes in addition to those promoted by physical exercise. On the contrary, in exercised animals, GH prevented those changes elicited by physical training in plasma glucose and lipids, oxidative status and endothelium-independent relaxation.